Stay updated on Maplirpacept in Hematologic Malignancies Clinical Trial
Sign up to get notified when there's something new on the Maplirpacept in Hematologic Malignancies Clinical Trial page.

Latest updates to the Maplirpacept in Hematologic Malignancies Clinical Trial page
- Check3 days agoChange DetectedRecord history shows multiple updates to core content, including study status, contacts/locations, and study description, across numerous versions. The latest version indicates termination of the study by Pfizer with no safety concerns reported.SummaryDifference0.1%

 - Check10 days agoNo Change Detected
 - Check31 days agoChange DetectedUpdated operating status notice and a new software version (v3.2.0) replacing the old v3.1.0.SummaryDifference9%

 - Check38 days agoChange DetectedUpdate: Revision from v3.0.2 to v3.1.0. This is a versioning change with no other substantive content alterations.SummaryDifference0.2%

 - Check53 days agoChange DetectedRevision updated from v3.0.1 to v3.0.2; the Back to Top link was removed.SummaryDifference0.5%

 - Check60 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content. There are no significant changes in core content or other important factors.SummaryDifference0.5%

 - Check67 days agoChange DetectedThe web page has undergone significant updates, including the addition of a facility name and location details, while removing specific state, country, and city information. This indicates a shift towards a more generalized presentation of location data.SummaryDifference48%

 
Stay in the know with updates to Maplirpacept in Hematologic Malignancies Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Maplirpacept in Hematologic Malignancies Clinical Trial page.